Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
latest_posts
- 1
Polar bears are rewiring their own genetics to survive a warming climate - 2'Euphoria' releases Season 3 photos with Zendaya, Sydney Sweeney, Jacob Elordi and others: See them
- 310 Famous Frozen yogurt Flavors All over The Planet
- 4The Longest Underwater Tunnel Connecting Germany and Denmark
- 5Three killed as unfinished building collapses on church service in Ghana
- Find the Captivating Professional flowerbeds of the US
- Figure out how to Keep up with Your Dental Inserts for Long haul Achievement
- Olivia Rodrigo announces 3rd album, 'You Seem Pretty Sad for a Girl So in Love,' set to debut in June
- Multi-million-euro win in Spanish lottery in doubt due to oversight
- Drones, physics and rats: Studies show how the people of Rapa Nui made and moved the giant statues – and what caused the island’s deforestation
- The 15 Best Business visionaries Under 40
- Scientists train to dive beneath polar ice as climate change warms the Arctic and Antarctica
- CMA Awards 2025: Full list of nominations, from Entertainer of the Year to Album of the Year
- Flu season is ramping up, and some experts are "pretty worried"
